Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial

DiscussionThe study design is based on experience from studies on apremilast in other inflammatory skin diseases using equivalent apremilast doses for approved indications. The trial may provide evidence for the use of apremilast in women with this burdensome genital dermatosis.Trial registrationClinicalTrials.govNCT0365666. Registered on 4 September 2018.
Source: Trials - Category: Research Source Type: clinical trials